IMPACT OF HOMOCYSTEINE ON COAGULATION FACTORS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Abstract

Today, according to the World Health Organization, COPD is one of the five leading causes of mortality, being a fatal diagnosis for 5% of the world population. Cardiovascular complications account for a significant proportion of the causes of death in patients with COPD. Hyperhomocysteinemia, as a predictor of atherosclerosis, may play a significant role in cardiovascular risk in COPD through stimulation of the coagulation cascade. The aim of the study was to determine the role of homocysteine in the activation of the coagulation cascade, as part of the increase in cardiovascular risk in COPD. Materials and methods. The study included 80 patients with an established diagnosis of COPD and 80 practically healthy individuals as a control group. Coagulation factors and blood homocysteine levels were determined. Results. The fibrinogen level increased significantly sharply in the groups of patients with HHC more than 4N, where the median fibrinogen was 1.3 times higher than the median in the 2-4N group, RFMC had the highest level in the group with increased GGC more than 2N, where the average level of RFMC was 1.2 times higher level of the group having GC up to 2N, the level of D-Dimer was most sensitive in increasing to the level of GC above 4N, where the average marker level exceeded the 2-4N group by 1.3 times. Conclusions. Hyperhomocysteinemia has an activating effect on the coagulation cascade, which may allow homocysteine to be considered as a predictor of hypercoagulation in COPD. This conclusion indicates the need to develop further measures for early diagnosis and treatment of cardiovascular risk in relation to the hyperhomocysteinemia factor.